Advertisement

Cancer Immunology, Immunotherapy

, Volume 62, Issue 3, pp 481–487 | Cite as

Up-regulation of Foxp3 participates in progression of cervical cancer

  • Chao Zeng
  • Yunhong Yao
  • Wei Jie
  • Miao Zhang
  • Xinrong Hu
  • Yi Zhao
  • Sen Wang
  • Jinbao Yin
  • Yulan Song
Original article

Abstract

Foxp3 was identified as a key protein in mediating inhibitory functions of regulatory T cell (Treg). Foxp3 was thought to express only in the T cell lineage until recently when some researches reported that Foxp3 was also expressed by cancer cells. In this study, we describe for the first time the expression of Foxp3 in cervical cancer. Progression from cervical intraepithelial neoplasia (CIN) to cervical cancer is a multistep process initiated by persistent infection with high-risk human papillomavirus (HPV). P16INK4a is a crucial marker of HPV integration into host cells. In the present study, expressions of Foxp3 and P16INK4a in CIN and cervical cancer were detected by immunohistochemistry. Our results found expression level of Foxp3 was increased during the progression of cervical neoplasia. Moreover, up-regulation of Foxp3 appeared to be correlated with the expression of P16INK4a. Examination of the role of Foxp3 in differentiation by double immunostaining for cytokeratin 10 (CK10) showed significant association between Foxp3 expression and differentiation (Foxp3 vs CK10). Furthermore, positive expression of Foxp3 was correlated with tumor size. These data suggest that Foxp3 may play an important role in differentiation and growth of cervical cancer cells. Our findings provide new insights regarding the role of Foxp3 in differentiation and its association with HPV infection during the development of cervical cancer.

Keywords

Foxp3 Cervical cancer P16INK4a Differentiation 

Notes

Acknowledgments

This work was supported by Initial Doctoral Funding of Guang Dong Medical College (B2011002).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Parkin D, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24:S11–S25CrossRefGoogle Scholar
  2. 2.
    Dehn D, Torkko KC, Shroyer KR (2007) Human Papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 111:1–14PubMedCrossRefGoogle Scholar
  3. 3.
    Coffer PJ, Burgering BM (2004) Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4:889–899PubMedCrossRefGoogle Scholar
  4. 4.
    Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:329–341PubMedCrossRefGoogle Scholar
  5. 5.
    Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRefGoogle Scholar
  6. 6.
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMedGoogle Scholar
  7. 7.
    Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423–5434PubMedCrossRefGoogle Scholar
  8. 8.
    Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S, Mori M (2008) Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 34:173–179PubMedCrossRefGoogle Scholar
  9. 9.
    Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344–8350PubMedCrossRefGoogle Scholar
  10. 10.
    Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746–1752PubMedCrossRefGoogle Scholar
  11. 11.
    Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P, Liu Y (2007) FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 117:3765–3773PubMedGoogle Scholar
  12. 12.
    Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P (2009) Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16:336–346PubMedCrossRefGoogle Scholar
  13. 13.
    Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8:457–462PubMedCrossRefGoogle Scholar
  14. 14.
    Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352PubMedCrossRefGoogle Scholar
  15. 15.
    Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang HY, Sun H (2010) Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett 28:791–797Google Scholar
  17. 17.
    Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS (2012) Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics 67:483–488PubMedCrossRefGoogle Scholar
  18. 18.
    Wang LH, Lin S, Wang JT (2010) Correlation between elevated FOXP3 expression and increase lymph node metastasis of gastric cancer. Chin Med J 123:3545–3549PubMedGoogle Scholar
  19. 19.
    Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T (2011) Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. Cancer Immunol Immunother 60:1109–1118PubMedCrossRefGoogle Scholar
  20. 20.
    Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75:95–101PubMedCrossRefGoogle Scholar
  21. 21.
    Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K (2008) The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol 21:617–625PubMedCrossRefGoogle Scholar
  22. 22.
    Bolzer K, Käser T, Saalmüller A, Hammer SE (2009) Molecular characterisation of porcine Forkhead-box p3 (Foxp3). Vet Immunol Immunopathol 132:275–281PubMedCrossRefGoogle Scholar
  23. 23.
    Boisvieux-Ulrich E, Le Pechon-Vallée C, Million K, Baeza-Squiban A, Houcine O, Guennou C, Reichert U, Marano F (2000) Differential effects of several retinoid receptor-selective ligands on squamous differentiation and apoptosis in airway epithelial cells. Cell Tissue Res 300:67–81PubMedCrossRefGoogle Scholar
  24. 24.
    Wang WH, Jiang CL, Yan W, Zhang YH, Yang JT, Zhang C, Yan B, Zhang W, Han W, Wang JZ, Zhang YQ (2010) FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol 16:5502–5509PubMedCrossRefGoogle Scholar
  25. 25.
    Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR (2008) Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer 114:474–480PubMedCrossRefGoogle Scholar
  26. 26.
    Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16 immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26:1389–1399PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Chao Zeng
    • 1
  • Yunhong Yao
    • 1
  • Wei Jie
    • 1
  • Miao Zhang
    • 3
  • Xinrong Hu
    • 1
  • Yi Zhao
    • 4
  • Sen Wang
    • 1
  • Jinbao Yin
    • 1
  • Yulan Song
    • 2
  1. 1.Department of PathologyGuangdong Medical CollegeDongguanChina
  2. 2.Department of PathologyThe First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouChina
  3. 3.Department of PathologyXin Hui Maternity and Child Health Care HospitalJiangmenChina
  4. 4.Department of ImmunologyGGuangdong Medical CollegeDongguanChina

Personalised recommendations